POMDOCTOR LIMITED Regains Compliance with Nasdaq Bid Price Requirement
PR Newswire•06/11/2026•16:05 ET
0
Key Highlights
- ➤POMDOCTOR regained Nasdaq’s $1.00 minimum bid-price compliance.
- ➤Nasdaq cancelled the November 12, 2026 hearing before its Hearings Panel.
- ➤POM shares will continue trading on Nasdaq under ticker POM.
- ➤Nasdaq had issued a delisting determination after 30 consecutive below-$1 closing bids.
POMDOCTOR LIMITED Regains Compliance with Nasdaq Bid Price Requirement PR Newswire
GUANGZHOU, China, Nov. 6, 2026 /PRNewswire/ -- POMDOCTOR LIMITED ("Pomdoctor" or the "Company") (NASDAQ: POM), a digital healthcare company focused on advancing AI-enabled healthcare solutions and predictive healthcare capabilities, today announced that on November 5, 2026, the Company received a letter (the "Compliance Letter") from The Nasdaq Stock Market LLC ("Nasdaq") informing the Company that it has regained compliance with the minimum bid price requirement of $1.00 per share under Nasdaq Listing Rule 5450(a)(1).
Get started
Create a free account to read the full story.